

Report for the Application Evaluation Decision

The effect of oral Semaglutide on bone turnover in patients with T2D: a randomized placebo-controlled clinical trial (SOBER II)

2023-505959-45-00

Decision
MSC:
Denmark
Decision:
Authorised
Reporting Date:
07/09/2023
Tacit decision:
No
Application Part:
Conditions:
Reason:
Justification:
Deferrals
Disagreement with Part I
Submission date:
07/09/2023